Clozapine is an established option when schizophrenia has not responded adequately to other appropriate antipsychotic trials. Treatment resistance requires careful assessment of dose, duration, actual exposure and persistent symptoms. Apparent failure can sometimes reflect interactions…Continue Reading
Clozapine binds to dopamine, serotonin, histamine, adrenergic and muscarinic receptors. Its laboratory affinity is relatively stronger at several non-D2 targets than at D2. This broad profile helps explain some effects, including sedation, postural dizziness and…Continue Reading
Clinical trials established that clozapine can help some people whose schizophrenia has not responded adequately to other antipsychotics. Benefit may involve reduced psychotic symptoms, distress or disruptive illness patterns. The extent and timing of improvement…Continue Reading
Serious clozapine risks include severe neutropenia, myocarditis, seizures and gastrointestinal hypomotility. Marked constipation can progress to dangerous bowel complications and should not be dismissed as a minor inconvenience. Sedation, low blood pressure and metabolic changes…Continue Reading
Clozapine monitoring includes blood counts to detect neutropenia and ongoing review of physical and mental health. Services also assess constipation, weight, metabolic measures, cardiovascular symptoms and other concerns according to local protocols. Monitoring is broader…Continue Reading